In a report published Wednesday, Stifel analyst Stephen Willey downgraded the rating on BioMarin Pharmaceutical BMRN from Buy to Hold, and removed the $70.00 price target.
In the report, Stifel noted, “We are downgrading shares of BioMarin from Buy to Hold – despite yesterday's largely positive R&D Day event highlighting what looks to be a sustainable pipeline of opportunities for years to come. We believe 1) risk/reward is appropriately priced in ahead of upcoming Vimizim regulatory events; 2) data flow should slow considerably post-ESMO; and 3) ascribing meaningful value to programs for which little/no data exists is required to get incrementally more positive on valuation at these levels.”
BioMarin Pharmaceutical closed on Tuesday at $75.96.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in